Reboxetine: tolerability and safety profile
in patients with major depression
by
Tanum L
Department of Psychosomatic
and Behavioural Medicine,
Rikshospitalet,
Oslo, Norway.
Acta Psychiatr Scand Suppl 2000; 402:37-40

ABSTRACT

Since reboxetine acts selectively on the reuptake of noradrenaline, it has a different side-effects profile than drugs acting predominantly on the serotonin reuptake mechanism. Data from patients treated with reboxetine (n = 1503) or placebo/comparator drugs (n = 1027) show that reboxetine has no significant cardiovascular effects, a low potential for drug interactions, causes no significant impairment of cognitive or motor function and no increase in suicidal ideation. In contrast to certain serotonergic drugs, there is no evidence of any withdrawal syndrome upon abrupt discontinuation or tapering of reboxetine treatment. Sexual dysfunction appears in only a small fraction of the patients and mainly with doses higher than 8 mg daily. The rate of discontinuation due to adverse effects with reboxetine was not significantly different from that observed with placebo in short-term studies. The level of efficacy and apparently favourable tolerability profile makes reboxetine an important alternative in the medical treatment of depressive illness.

Efficacy
Reboxetine
Noradrenaline
NARIs and SSRIs
Reboxetine: structure
Selectivity or multiplicity?
Noradrenaline and dopamine
Dopamine reuptake inhibition
Serotonin reuptake inhibition
Reboxetine versus fluoxetine
Noradrenaline reuptake inhibition
Reboxetine and major depression

Refs
and further reading

HOME
HedWeb
Nootropics
cocaine.wiki
Future Opioids
BLTC Research
MDMA/Ecstasy
Superhapiness?
Utopian Surgery?
The Abolitionist Project
The Hedonistic Imperative
The Reproductive Revolution
Critique of Huxley's Brave New World

The Good Drug Guide
The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family